Investors are focused today on the risk of more losses in more losses on companies that sell software and data-crunching tools as artificial intelligence revolutionizes corporate use of information.

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry and faces lower prices for ...

A structured end-of-life care model adapted for general practice shows improved symptom relief in patients, with nurses ...

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition ...

Shares of Novo Nordisk dropped roughly 18% in Denmark after the Ozempic and Wegovy maker warned that sales would decline more ...

Benchmark indices extended gains for a third straight session on Wednesday, recovering from a weak start as buying picked up ...

By Avinash P and Johann M Cherian Feb 4 (Reuters) - European shares edged lower on Wednesday, as shares of Novo Nordisk ...

COPENHAGEN, Feb 4 () - Novo Nordisk CEO Mike ​Doustdar said on ‌Wednesday that the price reductions ‌for its obesity drug ...

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter net income of ...

Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts projected.

Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: and is attached in iXBRL format.

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its ...